Chelsea and Westminster Hospital
NHS Foundation Trust

Chelsea and Westminster Hospital NHS Foundation Trust
Trust Medicines Group

Summary of Main Points from the Meeting held on Monday 23rd March 2020

2. Minutes and Summary Notes from last meeting

On account of the Trust response to the Covid-19 Pandemic, this meeting was held virtually. Decisions made at the meeting were supported by e-mail responses from regular meeting attendees.
The minutes and summary notes of the Medicines Group Meeting held on 27th January 2020 were approved.
The summary notes will be disseminated and published on the Trust intranet

3. Matters Arising

The Group noted the matters arising from the previous meeting.

4. Business to be transacted by the Medicines Group

a) Formulary Applications

Full Applications

- **Nil**

Ex-panel

- **Benzathine Penicillin 2.4 million units Injection**

Benzathine penicillin has recently been granted a product license for the treatment of Syphilis.
Up until now the Trust has been using the unlicensed product - Current usage is 4,200 vials per year.
The licensed product will be used in line with BASHH Guidelines as was the unlicensed product.
A PGD is being drafted to support nurse administration of Benzathine Penicillin in GUM as the product is now licensed.
Outcome: Approved for addition to the Formulary

- **Toujeo (Insulin Glargine) 300 units/ml in Doublestar Pen**

Requested by Endocrinology. This is similar to the same formulation that is on the formulary that comes in a Solostar pen with the exception that the pen itself can dial up to 160 units in one go compared to the 80 units with the Solostar pen.
There are currently a small number of patients who are on >80 unit doses who will benefit from using this new device as it will mean that there will be a need for few injections per day.
As this is not currently included on NWLIF prescribing will be undertaken by the CWFT.
Action: To check with the requestor if they are prepared to submit a NWLIF application before submitting a Trust formulary application/request

Removals

- **Nil**

NICE Approved drug applications

- **TA605 - Xeomin (Botulinum Neurotoxin Type A) for treating chronic Sialorrhoea**

Approved by NICE in October 2019
Outcome: Approved for addition to the Formulary

- **TA610 - Pentosan polysulfate sodium for treating bladder pain syndrome**

Approved by NICE in November 2019
Outcome: Approved for addition to the Formulary

- **TA624 - Peginterferon B1a for treating relapsing-remitting multiple sclerosis**

Approved by NICE in February 2020
Outcome: Approved for addition to the Formulary

Pharmacoeconomic Board requests

- **Anakinra for Haemophagocytic Lymphohistiocytosis**

Approved by Pharmacoeconomic Board on 20/01/2020
Outcome: Noted

- **Secukinumab for Psoriatic Arthritis**

Approved by Pharmacoeconomic Board on 03/02/2020
Outcome: Noted

- **Tocilizumab for Eosinophilic Fasciitis**

Approved by Pharmacoeconomic Board on 06/02/2020
Outcome: Noted

- **Rituximab for Cerebellar Autoimmune Encephalitis**

Approved by Pharmacoeconomic Board on 06/03/2020
Outcome: Noted

- **Alirocumab - Progressive atherosclerosis and familial hypercholesterolaemia**

Approved by Pharmacoeconomic Board on 12/03/2020
Outcome: Noted

- **Tocilizumab for Cerebellar Encephalitis (Rejection of IFR)**

Noting of rejection of IFR.
Outcome: Noted

Other

- **Compassionate Supply - Selinexor**

Compassionate supply from USA for Selinexor 20mg Tablets for the management of Refractory Relapsed Multiple Myeloma. Approved by Chair's Action on 03/02/2020
Outcome: Noted

4.2 Trust Medicines Policy

- **Trust Medicines Policy - Section 6 - Controlled Drugs**

Updated to include the following preparations assigned Controlled Drug status in Trust during Cronovirus Pandemic:
Kaletra® (Lopinavir/Ritonavir) 80mg/20mg/ml Liquid
Kaletra® (Lopinavir/Ritonavir) 100mg/25mg Tablets
Kaletra® (Lopinavir/Ritonavir) 200mg/50mg Tablets
Chloroquine 250mg Tablets
Hydroxychloroquine 200mg Tablets has also been added to the above list.
Outcome: Approved

- **Trust Medicines Policy - Section 15 - Clinical Trials**

Scheduled review and update.
Outcome: Approved

- **Risk Assessment for BCG vaccine at Queen Mary's Maternity Unit (WMUH)**

Newly drafted Risk Assessment for the management of BCG vaccine at Queen Mary's Maternity Unit (WMUH) to reduce the risk of contamination and tampering when doses are pre-drawn up into multiple syringes and stored in the locked treatment room fridge.
Outcome: Approved

- **Policy for Sexual Health Advisors to issue Tenofovir/Emtricitabine and Raltegravir under Patient Specific Direction for HIV Post Exposure prophylaxis for sexual exposure (PEPSE)**

New policy to permit issue of PEPSE to be issued to patients by non-registered Sexual Health Advisors
Outcome: Approved

- **Policy for sexual Health Advisors to issue Tenofovir/Emtricitabine under Patient Specific Direction for HIV Pre-Exposure prophylaxis for sexual exposure (PrEP)**

New policy to permit issue of PrEP to be issued to patients by non-registered Sexual Health Advisors.
Outcome: Approved

- **Trust Medicines Policy - Section: 34 - Supply and administration of medicines by Non-registered Healthcare Practitioners**

Update to include the issue of PEPSE and PrEP to patients by non-registered Sexual Health Advisors.
Outcome: Approved

- **Updated to Trust Adult IV Administration Guide**

Temporary update to allow Chemotherapy and Systemic Anti-Cancer Therapy to be administered on David Erskine Ward and St. Steven's in light of the ward changes during Covid-19 Pandemic.
Outcome: Approved

4.3 Medicines Optimisation

- **NWL Cost saving initiatives**

Feedback from consultation on cost saving initiatives being proposed by NWL CCG
Decision: Deferred to the next meeting

4.4 NICE Technical Appraisals and Guidance

a) NICE Technical Appraisals

4 Appraisals published in January 2020

TA618 - Atezolizumab with carboplatin and nab-paclitaxel for untreated advanced non-squamous non-small-cell lung cancer (Terminated appraisal)
Formulary status / Action
Nil - Terminated appraisal

TA619 - Palbociclib with fulvestrant for treating hormone receptor-positive, HER2-negative, advanced breast cancer
Formulary status / Action
Currently included on the formulary.
Numbers likely to treat at CWH site: 0 patients per year - Condition not treated at CWH Site
Numbers likely to treat at WMUH site: 5-6 patients per year

TA620 - Olaparib for maintenance treatment of relapsed platinum-sensitive ovarian, fallopian tube or peritoneal cancer
Formulary status / Action
Nil action - Not applicable - CWFT not commissioned

TA621 - Osimertinib for untreated EGFR mutation-positive non-small-cell lung cancer
Formulary status / Action
Nil - Not recommended

b) NICE Technology Appraisals published in February 2020

3 Appraisals published in February 2020

TA622 - Sotagliflozin with insulin for treating Type 1 Diabetes
Formulary status / Action
Add to the formulary following receipt of a signed application form from the Endocrinology Team.

TA623 - Patiromer for treating hyperkalaemia
Formulary status / Action
Currently included on the formulary.
Numbers likely to treat at CWH site: 10 patients per year
Numbers likely to treat at WMUH site: 12 patients per year

TA624 - Peginterferon beta-1a for treating relapsing–remitting multiple sclerosis
Formulary status / Action
Add to the formulary following receipt of a signed application form from the Neurology Team - Application Form included under Section 4.1

c) NICE Highly Specialised Technologies published since last meeting

0 Highly Specialised Technologies published

4.5 IVIG requests

- **IVIG Issues for January 2020 - CWH Site - Approved by the IVIG Approval Panel**

There were 9 IVIG issues, with 2 new requests
Outcome: Noted

- **IVIG Issues for January 2020 - WMUH Site**

Outcome: Deferred to next meeting

- **IVIG Issues for February 2020 - CWH Site - Approved by the IVIG Approval Panel**

There were 7 IVIG issues, with 2 new requests:
Outcome: Noted

- **IVIG Issues for February 2020 - CWH Site**

Outcome: Deferred to next meeting
Decision: Approved

4.6 Items for noting

- **Quarterly Controlled Drug Summary Report - Q3 2019/20**

Quarterly Controlled Drug Summary Report for Q3 2019/20
Outcome: Noted

- **Quarterly Controlled Drugs Accountable Officer Report - Q3 2019/20**

Quarterly CD Accountable Officer Report for Q3 2019/20
Outcome: Noted

- **Trust Patient Safety Group Report - March 2020**

Trust Patient Safety Group Report covering period of October 2019 to February 2020
Outcome: Noted

- **CPP Monthly Report - January 2020**

Clinical Commissioning Pharmacy Report for January 2020
Outcome: Noted

- **Medication Shortage Log - March**

Medication Shortage Log for March

Outcome: Noted

- **Medicines Safety Bulletin - Medication related incidents**

Medicines Safety Bulletin re Adrenaline Auto-Injectors - Published February 2020
Outcome: Noted

- **Medicines Safety Bulletin - Adrenaline Auto-injectors**

Medicines Safety Bulletin re Adrenaline Auto-Injectors - Published March 2020
Outcome: Noted

- **MHRA Drug Safety Update - January 2020**

MHRA update for January 2020
Outcome: Noted

- **MHRA Drug Safety Update - February 2020**

MHRA update for February 2020
Outcome: Noted

4.7 Meeting minutes for noting

- **Antibiotic Steering Group - January 2020**

Minutes from Antibiotic Steering Group meeting - January 2020
Outcome: Noted

- **Medication Safety Group - February 2020**

Minutes from Medication safety Group meeting - February 2020
Outcome: Noted

- **HIV/GUM Directorate Medicines Sub-Group Meeting - January 2020**

Minutes from HIV/GUM Directorate Medicines Sub-Group meeting - January 2020
Outcome: Noted

- **HIV/GUM Directorate Medicines Sub-Group Meeting - February 2020**

Minutes from HIV/GUM Directorate Medicines Sub-Group meeting - February 2020
Outcome: Noted

4.8 Additional papers to go to Trust Patient Safety Group

- **Quarterly Controlled Drug Summary Report - Q3 2019/20**
- **Quarterly Controlled Drugs Accountable Officer Report - Q3 2019/20**
- **Trust Patient Safety Group Report - March 2020**

5. Any other business

Nil

6. Date of next meeting

Date: 27th April
Time: 8am-9am
Location: Main Boardroom (CWH) and meeting room A (WMUH)
Closing date: 9th April 2020